Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Juvista in Scar Revision Surgery
NCT00742443Phase 3Completed
- Sponsor
- Renovo
- Start
- Dec 2008
- Primary completion
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of avotermin in cicatrix (3 arms), sponsored by Renovo. Primary endpoint: Global Scar Comparison Scale at 12 months. Started Dec 2008; status: completed.
02
Drugs
avotermin
03
Conditions
cicatrix
Beyond the preview
Go deeper on NCT00742443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00742443.